{"entity":{"id":"egl-002","kind":"drug","name":"EGL-002","aka":["anti-CCR8-IL2m"],"tldr":"EGL-002 is an experimental anti-CCR8 / IL-2 mutein fusion antibody from Egle Therapeutics, in preclinical development for solid tumours.","summary":"EGL-002 (anti-CCR8-IL2m) is an anti-CCR8 / IL-2 mutein fusion antibody (targeted IL-2m) from Egle Therapeutics. An anti-CCR8/IL-2 mutein fusion antibody engineered to enhance depletion of regulatory T cells in solid tumours; by binding both CCR8 and CD25 it stays on the surface of tumour-infiltrating Tregs longer. Its furthest stage is preclinical development, for solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Homepage pipeline bar for anti-CCR8-IL2m fills Discovery and Preclinical, not IND-enabling; preclinical posters at AACR 2025. No registered trial found for EGL-002. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Egle Therapeutics: egle-tx.com","url":"https://www.egle-tx.com/egle-therapeutics-to-highlight-novel-preclinical-findings-for-regulatory-t-cells-targeting-programs-egl-001-and-egl-002-with-poster-presentations-at-the-2025-aacr-annual-meeting/"},{"label":"Egle Therapeutics: egle-tx.com","url":"https://www.egle-tx.com/"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["cd25"],"drugs":[],"companies":["egle-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"EGL-002","modality":"Anti-CCR8 / IL-2 mutein fusion antibody (targeted IL-2m)","mechanism":"An anti-CCR8/IL-2 mutein fusion antibody engineered to enhance depletion of regulatory T cells in solid tumours; by binding both CCR8 and CD25 it stays on the surface of tumour-infiltrating Tregs longer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/egl-002/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/"}],"company":[{"id":"egle-therapeutics","kind":"company","name":"Egle Therapeutics","route":"/companies/egle-therapeutics/"}]}}